Janux Therapeutics’ Post

📈 The data have spoken: Testing before treatment initiation is a crucial component in delivering better health outcomes for lung cancer patients. Researchers at the University of Pennsylvania found that non-small cell lung cancer patients who underwent molecular testing before starting first-line treatment lived nearly four times longer than those who didn’t. These results reinforce why we push for every patient at every stage to have to get biomarker testing: to ensure that they receive the most effective medicine for their unique disease. Explore the results in depth here: https://lnkd.in/e2bSHvb9 #LungCancer 🫁

Interested in hearing the latest updates on the Nuvalent clinical trial focused on ALK-positive cancer? Nuvalent is hosting a conference call and live video webcast on October 13th at 8am EST. Learn more here: #nuvalent #cancer #oncology #alkpositive #alkpositivecancer

MacroGenics, Inc. has shared data from the Phase 2 TAMARACK study of vobramitamab duocarmazine (vobra duo, previously known as MGC018) in patients with metastatic castration-resistant prostate cancer (mCRPC). Early interim safety data from the Phase 2 TAMARACK study (NCT05551117), including comparison to retrospective analysis from a Phase 1 study (as submitted in an ASCO abstract that was not accepted), is included in the press release. Overall conclusions are: Preliminary safety data from TAMARACK suggest that reducing the dose and frequency of vobra duo improves its safety and tolerability in men with mCRPC. The company plans to provide updated interim data, including safety and preliminary efficacy, by May 31. #mabs #adcs https://lnkd.in/eE57D7mu

🌟 Revolutionizing Oncology Trials with Precision Insights 🌟 Hello Innovators in Oncology, At Simsen Diagnostics , we're on a mission to Unleash Insight, One Blood Sample at a Time. Our cutting-edge ultrasensitive ctDNA technology is transforming how cancer is diagnosed and monitored, offering unparalleled precision and early detection capabilities. 🔍 Why should this matter to you? Accelerate Drug Development: Our technology can significantly reduce the time from trial initiation to actionable insights, enabling faster decision-making in your clinical trials. Enhance Trial Outcomes: By providing deeper insights into disease progression and treatment efficacy, Simsen Diagnostics empowers pharmaceutical companies to develop more effective oncology drugs. Personalized Medicine: Leverage our diagnostic solution to tailor treatments to individual patient profiles, paving the way for groundbreaking personalized therapies. 🌊 Imagine what we can achieve together. Are you ready to dive deeper into precision oncology? We invite pharmaceutical companies developing oncology drugs to explore how Simsen Diagnostics can elevate your clinical trials. Let's unlock new possibilities in cancer treatment and bring hope to patients worldwide. 💡 Contact us today to learn more and start a conversation about transforming your next clinical trial with Simsen Diagnostics. www.simsendiagnostics.com inbox@simsendiagnostics.com #Oncology #ClinicalTrials #PrecisionMedicine #CancerResearch #DrugDevelopment #SimsenDiagnostics

A short and sweet article about the combination of ADCs with immune modulators!

Mythic Therapeutics, Inc. announced promising initial results from the Phase 1 KisMET-01 study of MYTX-011, a novel cMET-targeting ADC, in treating advanced or metastatic non-small cell lung cancer (NSCLC). The study, presented at the ASCO Annual Meeting, showed MYTX-011 was well-tolerated with no dose-limiting toxicity and demonstrated nearly dose-proportional pharmacokinetics. The study continues to assess safety, tolerability, and preliminary anti-tumor activity, with further efficacy data to be presented in the future. The findings offer hope for patients with diverse cMET expression levels. #HemiBio Brian Fiske https://lnkd.in/epvx2gPC

HCB101, an engineered extracellular domain of SIRPα fused to the Fc region of IgG4 as the foundation of the innate immunity checkpoint #immunotherapy , is HanchorBio Inc. 漢康生技股份有限公司 first candidate. We’re deeply grateful to our first patient, investigators/researchers, this clinical sites in US and Taiwan, our CRO, vendors, and consultants whose participation and dedication have played a critical role in advancing our Phase 1 study (NCT05892718). The initiation of this study of HCB101 is an important achievement that brings us closer to delivering a potential new treatment which may have a life-changing impact for #cancer patients who do not respond to currently available #treatment options and can result in death. #biotechnology #oncology #medicine https://lnkd.in/e4yTdhN6

An early-stage clinical trial of a radiopharmaceutical drug developed by Johnson & Johnson showed some signs of efficacy in prostate cancer patients, according to data released ahead of ASCO, but four participants in the trial died. Patient deaths are not unheard of in early-stage testing. But these cases could give pause to other drug developers, as Johnson & Johnson is one of the first to report clinical data on a next-generation isotope that is theorized to be safer. It may also hamper how much Johnson & Johnson can increase the dose of JNJ-6420 in order to boost the response rate. What do you think about the radiopharmaceutical data? #radiopharmaceuticals #ASCO #ASCO2024 #pharma #cancer #oncology #drugdevelopment #clinicaltrials #radiation

Are #PSMAfore data clear, convincing enough to lift Novartis’ #Pluvicto? To find out Pluvicto’s prospects for shaking things up in prostate cancer, we are asking an expert. Learn more here: https://lnkd.in/guqXVSjZ #Novartis #pharmaceuticals

New Drugs on the Horizon sessions feature first disclosures of 12 new anticancer therapies This year's three New Drugs on the Horizon sessions featured first disclosures on the structure, mechanism of action, and functional target modulation of 12 novel cancer agents